These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19829021)

  • 1. Methodology of superficial bladder cancer trials: objective evaluation of treatment - the need for standardization.
    Bassi PF; Volpe A; Racioppi M; D'Agostino D; Gardi M; Totaro A; Pinto F; Sacco E; Bongiovanni L
    Urol Int; 2009; 83(3):258-63. PubMed ID: 19829021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Methodology of clinical trials for non-muscle infiltrating bladder cancer. Objective evaluation: standardization requirements].
    Volpe A; Racioppi M; D'Agostino D; Cappa E; Gardi M; Totaro A; Sacco E
    Urologia; 2008; 75(4):207-13. PubMed ID: 21086334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response criteria for phase III studies of superficial bladder cancer.
    Schröder FH; Sylvester R; Gustafson H; Kawai T; Kurth KH; Matsuda M; Miyakawa M; Newling DW; Studer E
    Prog Clin Biol Res; 1986; 221():311-21. PubMed ID: 3543946
    [No Abstract]   [Full Text] [Related]  

  • 4. Searching for novel therapeutics and targets: insights from clinical trials.
    Mitra AP; Cote RJ
    Urol Oncol; 2007; 25(4):341-3. PubMed ID: 17628305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advantages of multifactorial analysis of correlations (Benzekri's method) in practice and in clinical research. A simplified example of its application to bladder tumors].
    Bittard M; Dagras G; Bittard H
    Ann Urol (Paris); 1988; 22(5):359-62. PubMed ID: 3202609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardization of format of reporting results.
    Dalesio O; Barton B; Hisazumi H; Hilgar A; Staquet M; Tagnon H; Uyama T
    Prog Clin Biol Res; 1986; 221():15-31. PubMed ID: 3809181
    [No Abstract]   [Full Text] [Related]  

  • 7. Standardization of protocol format.
    Sylvester R; Griffin P; Koiso K; Hilgar A; Kumazawa J; Matsumura Y
    Prog Clin Biol Res; 1986; 221():3-13. PubMed ID: 3809186
    [No Abstract]   [Full Text] [Related]  

  • 8. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.
    Valent P; Akin C; Escribano L; Födinger M; Hartmann K; Brockow K; Castells M; Sperr WR; Kluin-Nelemans HC; Hamdy NA; Lortholary O; Robyn J; van Doormaal J; Sotlar K; Hauswirth AW; Arock M; Hermine O; Hellmann A; Triggiani M; Niedoszytko M; Schwartz LB; Orfao A; Horny HP; Metcalfe DD
    Eur J Clin Invest; 2007 Jun; 37(6):435-53. PubMed ID: 17537151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing the evaluation of an article in cancer literature.
    Kumaraswamy ; Supe SS; Ramesh C
    Indian J Cancer; 1999; 36(2-4):69-79. PubMed ID: 10921210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical analysis techniques and sample size determination for clinical trials of treatments for bladder cancer.
    Byar D; Kaihara S; Sylvester R; Freedman L; Hannigan J; Koiso K; Oohashi Y; Tsugawa R
    Prog Clin Biol Res; 1986; 221():49-64. PubMed ID: 3809188
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimizing outcomes at every stage of bladder cancer: do we practice it?
    Herr H; Konety B; Stein J; Sternberg CN; Wood DP
    Urol Oncol; 2009; 27(1):72-4. PubMed ID: 19111802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Nordic experience of cooperative urinary bladder cancer trials.
    Malmström PU; Rintala E; Hellsten S
    Semin Urol Oncol; 2001 Feb; 19(1):69-70. PubMed ID: 11246738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutics for patients with non-muscle-invasive bladder cancer.
    Svatek RS; Kamat AM; Dinney CP
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):807-13. PubMed ID: 19496717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life assessment in bladder cancer clinical trials: conceptual, methodological and practical issues.
    Aaronson NK; Calais da Silva F; Yoshida O; van Dam FS; Fosså SD; Miyakawa M; Raghavan D; Riedl H; Robinson MR; Worden JW
    Prog Clin Biol Res; 1986; 221():149-70. PubMed ID: 3543941
    [No Abstract]   [Full Text] [Related]  

  • 15. EORTC Genitourinary Group Monograph 3: Developments in bladder cancer. Proceedings of the First International Consensus Development Conference on Guidelines for Clinical Research in Bladder Cancer. Antwerp, Belgium, June 20-22, 1985.
    Prog Clin Biol Res; 1986; 221():1-328. PubMed ID: 3543940
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer patient advocacy: new opportunities for treatment advances.
    Quale DZ; Droller MJ
    Urol Oncol; 2007; 25(4):351-2. PubMed ID: 17628308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials referral resource. Bladder cancer.
    Cheson BD
    Oncology (Williston Park); 1992 Jan; 6(1):105-6. PubMed ID: 1531596
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer.
    Black PC; Brown GA; Dinney CP
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):1015-26. PubMed ID: 17627461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Databases and the future of clinical trials in bladder cancer.
    Adams RM
    Urol Oncol; 2007; 25(4):330-2. PubMed ID: 17628302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARC-CTOS imaging symposium: introduction to the problem from a clinical perspective.
    Benjamin RS
    Oncologist; 2008; 13 Suppl 2():1-3. PubMed ID: 18434630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.